8/2/2022 4:11:57 PM
Rigel Pharma Q2 Loss/share $0.08, Same As Last Year
6/8/2022 7:02:44 AM
Rigel Says FORWARD Phase 3 Trial Of Fostamatinib Did Not Demonstrate Statistical Significance In Primary Endpoint
5/24/2022 8:27:17 AM
Knight Therapeutics Enters License And Supply Deals With Rigel Pharma To Commercialize Fostamatinib In Latin America
5/3/2022 4:04:33 PM
Rigel Pharma Q1 Loss/share $0.16 Vs. Profit $0.22 Year Ago
4/8/2022 7:32:06 AM
Rigel Announces Grant Of Stock Options To Purchase Aggregate Of 626,000 Shares To 15 Newly Hired Employees
3/8/2022 8:14:42 AM
Rigel : Data From Phase 2 Study Of Fostamatinib For Warm Antibody Autoimmune Hemolytic Anemia Treatment Published
3/1/2022 4:06:59 PM
Rigel Pharma Q4 Loss/share $0.13 Vs. Loss $0.11 Year Ago
1/10/2022 8:43:47 AM
Rigel Pharma Expects To Report Total Revenue Of Approximately $20.4 Mln In Q4